Piper Jaffray Provides Color on Biotechnology

Piper Jaffray provided color on biotechnology. In a research report published today, Piper Jaffray commented on two new drugs, Novo Nordisk's degludec and BMS and AstraZeneca's dapagliflozin. In the report, Piper Jaffray states, “We attended the American Diabetes Association conference, where there was significant interest in Novo Nordisk's degludec (once daily insulin) and BMS and AstraZeneca's dapagliflozin, an SGLT2 inhibitor. Based on conversations with physicians' at the ADA, degludec has the potential to take share from Lantus and the combination of degludec and Victoza to expand the GLP-1 market. For dapagliflozin, imbalance in certain cancers and infection risk will be focus on FDA advisory panel meeting on July 19th.”